Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Akimoto Yamada"'
Autor:
Hiroyuki Hasegawa, Tsuyoshi Gotoh, Akimoto Yamada, Koutarou Nogami, Kazuo Mimura, Masaru Umeda, Mitsuhiro Yamamoto, Nobuhide Izumi
Publikováno v:
Nihon Toseki Igakkai Zasshi. 30:109-115
オフロキサシン (OFLX) の光学活性体であるレボフロキサシン (LVFX) の抗菌力, 薬物動態を血液透析 (HD) 患者で検討した. LVFXの阻止円面積は1-2μg/mlの濃度範囲内ではOFLXの約1.3-1.6倍を示した.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3b3236fdfa5516bc7c3d22f0e1dfb94
https://doi.org/10.4009/jsdt.30.109
https://doi.org/10.4009/jsdt.30.109
Autor:
Yuna Onaka, Tomoko Hirai, Megumi Kuroko, Akimoto Yamada, Seizaburo Okada, Hisako Negi, Manai Yamamoto
Publikováno v:
Drug Information Journal. 29:1201-1209
Drug information (DI) activities are a fundamental service of pharmaceutical companies. Daiichi Pharmaceutical Co., Ltd. receives approximately 21,000 inquiries a year. It has developed its own computerized DI tracking system and has analyzed these i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::816bb5a233170975e4a75ddacc859097
https://doi.org/10.1177/009286159502900418
https://doi.org/10.1177/009286159502900418
Autor:
Akimoto Yamada, Kumi Morishita, Munehiro Tomikawa, Yoshiaki Nakai, Yoji Yoshida, Suguki Imoto, Kaori Ishikawa, Masatoshi Mogaki, Kyoko Hasegawa, Hideki Kanai, Motoi Sasuga, Masanao Ishihara
Publikováno v:
The Journal of Japan Atherosclerosis Society. 18:839-850
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9d7845ea6645097c8761069fbb0f645
https://doi.org/10.5551/jat1973.18.9-10_839
https://doi.org/10.5551/jat1973.18.9-10_839
Autor:
Miki Toshikura, Mika Yoshida, Shoichi Funabashi, Akimoto Yamada, Kazuko Yoshioka, Kunihisa Nasu, Seizaburo Okada, Akira Kosasayama
Publikováno v:
Pharmacoepidemiology and drug safety. 8(1)
We surveyed the safety and effectiveness of 13 drug products under the reexamination system in Japan. Until the time of reexamination, a total of 106,328 case reporting forms were collected in the drug use investigations, while 1340 adverse drug reac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f808a7b1d6a5b5624e398a5024c313be
https://pubmed.ncbi.nlm.nih.gov/15073944
https://pubmed.ncbi.nlm.nih.gov/15073944
Publikováno v:
Toxicology and Applied Pharmacology. 44:431-439
Budralazine, 1-[2-(1,3-dimethyl-2-butylidene)-hydrazino]-phthalazine, an antihypertensive drug, has been evaluated toxicologically in mice and rats. The acute oral toxicity of budralazine was 10 and 2 times lower in mice and rats, respectively, than
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31548e88f55b0d5fcafd06d987c85a77
https://doi.org/10.1016/0041-008x(78)90251-x
https://doi.org/10.1016/0041-008x(78)90251-x
Autor:
Hidemasa Ogawa, Akimoto Yamada
Publikováno v:
EXPERIMENTAL ANIMALS. 24:151-155_4
Ulcerative entero-colitis was developed in 6-week-old male Sprague-Dawley rats treated daily with ACTH (4 mg/kg. s. c.) as well as necrotic purulent lesions in liver, kidney, lung or heart. Incidence of ulcerative lesions was 6.3% in Farm-A rats and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f8c51f3db68c9e6498373f7eefa7821
https://doi.org/10.1538/expanim1957.24.4_151
https://doi.org/10.1538/expanim1957.24.4_151